According to a new report by Polaris Market Research, the MENA Gaucher Disease Treatment market was valued at USD 136.66 million in 2024 and is projected to reach USD 178.35 million by 2034, expanding at a CAGR of 2.8% over the forecast period. Growth is underpinned by the expansion of centralized healthcare systems, growing public-private partnerships, and rising investment in rare disease diagnostics across key MENA countries.

What Is Driving MENA Gaucher Disease Treatment Market Growth?

Demand is climbing as centralized GCC healthcare procurement converges with expanding rare-disease policy agendas. Manufacturers and health systems are prioritizing early diagnosis and enzyme replacement therapy access, pushing Gaucher disease treatment adoption across Saudi Arabia, Iran, and Turkey. Polaris analysts note that Abu Dhabi's Department of Health partnered with AstraZeneca in June 2024 to establish a Rare Diseases Centre of Excellence, positioning the region for sustained treatment-access growth through 2034, with Type 1 disease emerging as the largest revenue contributor and Type 2 posting steady incremental gains in specialized pediatric care.

Key Trends Shaping the MENA Gaucher Disease Treatment Industry

Centralized Healthcare Procurement

The expansion of centralized healthcare systems across GCC countries is reshaping the competitive landscape, enabling coordinated funding mechanisms and better-negotiated treatment costs for enzyme replacement therapies.

Rising Public-Private Partnerships

Multinational pharmaceutical firms are forming alliances with national health ministries, such as EVERSANA's collaboration with Vector Pharma (UAE), expanding the regulatory landscape for rare-disease commercialization across the Middle East and North Africa.

Oral Substrate Reduction Therapy Adoption

Growing preference for oral substrate reduction therapy over infused enzyme replacement therapy is shifting the market outlook, as faster orphan-drug approvals ease market entry for novel oral agents.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/middle-east-and-north-america-mena-gaucher-disease-treatment-market 

Market Segmentation: Breaking Down the MENA Gaucher Disease Treatment Market

Polaris segments the MENA Gaucher disease treatment market by type, therapy, distribution channel, and country, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The Type 1 segment led the market in 2024, generating USD 104.09 million on the strength of rising early diagnosis and government-backed rare disease programs in the UAE and Saudi Arabia. The Type 2 segment is projected to reach USD 2.91 million by 2034 as regional health authorities in Qatar and the UAE prioritize neonatal screening and pediatric research partnerships.

By Therapy

Substrate reduction therapy accounted for 25.76% of revenue in 2024, gaining ground among patients unable to tolerate enzyme replacement therapy due to its oral administration convenience and faster orphan drug approvals in Gulf countries.

By Distribution Channel

Retail pharmacies accounted for 68.40% of revenue in 2024, becoming the primary access point for prescription rare-disease therapies as urban hubs such as Riyadh, Dubai, and Cairo expand community pharmacy infrastructure, signaling where near-term demand around “rare disease pharmacy access” is concentrated.

Regional Outlook: Where Is MENA Gaucher Disease Treatment Growing Fastest?

Saudi Arabia led the market in 2024, accounting for 21.62% share on the back of strong healthcare infrastructure and increased Ministry of Health funding for rare disease programs, while Turkey is expected to post the fastest growth, projected to reach USD 24.79 million by 2034, driven by national health insurance coverage and its role as a regional clinical trial hub. Within the region, Iran remains a significant market with 13.95% share in 2024, supported by domestic biosimilar production, while Morocco and Libya round out emerging markets, supported by expanding genetic testing services and international NGO partnerships.

Competitive Landscape: Leading MENA Gaucher Disease Treatment Companies

Key players profiled in the report include Sanofi, Takeda Pharmaceutical, Amicus Therapeutics, and Protalix Biotherapeutics, who are focusing on strategic licensing and regional expansion to strengthen market position across the Type 1 and retail pharmacy segments outlined above. Recent moves include ISU Abxis's December 2024 launch of Abcertin in the MENA market following an exclusive licensing deal with Saudi Arabia's Tabuk Pharmaceuticals, aimed at deepening share in Saudi Arabia and the broader Gulf region.

Why It Matters for Buyers Evaluating Rare Disease Market Entry

For stakeholders researching MENA Gaucher disease treatment market share, this report benchmarks segment-level pricing and forecast data — by type, therapy, distribution channel, and country — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking substrate reduction therapy as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Offshore Wind Energy Market

Oncology Clinical Trials Market

Sleeping Aids Market

Europe Veterinary Clinical Trials Market

Drilling Polymers Market

Drilling Polymers Market

Tool Steel Market

Skin Care Products Market

Connected Enterprise Market